Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Unknown 1

Sponsor Class

OTHER 2NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Oligodendroglioma 2Central Nervous System Neoplasms 2Astrocytoma 2Urinary Bladder Neoplasms 1Urethral Neoplasms 1Spinal Cord Neoplasms 1Rhabdoid Tumor 1Optic Nerve Glioma 1Medulloblastoma 1Gliosarcoma 1Glioma, Subependymal 1Glioma 1Glioblastoma 1Familial ependymoma 1Ependymoma 1Choroid Plexus Neoplasms 1Breast Neoplasms, Male 1Breast Neoplasms 1Brain Neoplasms 1

Interventions

Temozolomide 11Radiotherapy 6Lomustine 3Vincristine 2Procarbazine 2Carmustine 2veliparib 1trametinib 1selinexor 1ribociclib 1lonafarnib 1dabrafenib 1carmustine, poliferprosan 20 drug combination 1Watchful Waiting 1Topotecan 1Radiotherapy, Intensity-Modulated 1Radiotherapy, Conformal 1Psychiatric Rehabilitation 1Platelet Count 1Panobinostat 1Neoadjuvant Therapy 1Mental Status and Dementia Tests 1Magnetic Resonance Spectroscopy 1Imatinib Mesylate 1Hydroxychloroquine 1Everolimus 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NETWORK × Glioma × lonafarnib × Clear all
NCT00083096 2015-02-10

Lonafarnib and Temozolomide in Treating Patients With Recurrent Primary Supratentorial Gliomas

European Organisation for Research and Treatment of Cancer - EORTC

Phase 1 Unknown
30 enrolled
CNSSarcoma

Astrocytoma, Brain Neoplasms, Ependymoma, Glioblastoma, Glioma, Oligodendroglioma, Central Nervous System Neoplasms, Glioma, Subependymal, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡